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Abstract
Background: Itch is a prominent feature of many skin diseases, particularly atopic dermatitis and cutaneous
mastocytosis. Sodium cromoglicate (SCG), a chromone developed for the treatment of allergic disease has been
shown to reduce the severity of itch when applied topically to subjects with atopic dermatitis. The aim of this
study was to investigate whether topical sodium cromoglicate can reduce the severity of itch induced by
intradermal histamine.
Methods: SCG was introduced into the skin of healthy volunteers both by iontophoresis and by topical application
using a new 4% cutaneous emulsion (Altoderm™). The skin was then challenged with intradermal histamine.
Measurements were made of severity of itch, size of wheal and flare and change in blood flux
Results: SCG significantly reduced the severity of itch (P = 0.0045) and flare (P = 0.0143) when delivered by
iontophoresis. SCG 4% cutaneous emulsion significantly reduced severity of itch (P = 0.024) and flare (P = 0.015) in
atopic subjects. Trend analysis showed increasing effect on itch with increased concentrations of SCG, which was
significant (P = 0.046). There were no effects on wheal or blood flux.
Conclusions: Topically applied SCG, administered in a new cutaneous emulsion base, significantly reduced the itch
and flare caused by intradermal histamine. The effect was greatest in atopic subjects and increased with the
concentration of SCG in the emulsion.
Trial registration: ISRCTN35671014
Background
Itch is a prominent feature of many skin diseases, parti-
cularly atopic dermatitis and cutaneous mastocytosis.
Itch can be triggered by local, systemic, peripheral or
central stimuli. The transmission of itch to the brain is
the function of a sub-population of the dense nerve net-
work in the skin, unmyelinated C-neurons, which are
histamine sensitive [1]. Intradermal injection of hista-
mine into human skin results in a wheal, flare, erythema
and itch. It therefore represents a useful model for
investigating treatments that might reduce itch severity.
Sodium cromoglicate (SCG), a chromone developed in
the 1960’s as an inhaled powder for the treatment of
asthma [2] has subsequently been used for the treatment
of allergic rhinitis, allergic conjunctivitis, food allergy
and systemic mastocytosis. A number of studies have
investigated the effect of topically applied SCG in atopic
dermatitis [3-7]. Although variable effects have been
reported, probably because of the hydrophilic nature of
SCG that limits its penetration in intact skin [6], several
have found a significant reduction of itch [3-5].
While mast cell stabilization was proposed as the pri-
mary mode of action of SCG in the treatment of asthma
[2], this is unlikely to be its primary mechanism of
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inhibit histamine release from human skin mast cells in
experimental models in vitro [8] or in vivo [9]. Second,
while it can reduce both histamine-induced itch and
flare, it does not reduce the wheal [10]. The most likely
mechanism of action is to prevent the activation of sen-
sory nerves. This was initially proposed from airway stu-
dies in humans [11,12] and experimental animals [13].
This proposal is supported by a study with the related
chromone, nedocromil sodium, which, when introduced
into the skin by iontophoresis, causes inhibition of hista-
mine-induced itch and flare but has no effect on the
wheal [14]. Further studies with nedocromil sodium have
shown it to reduce sensory nerve activation, critical in
causing both itch and flare by inhibiting a Na
+/K
+/2Cl
-
co-transporter in the sensory nerve membrane [15].
Our hypothesis was that SCG will have a similar effect
on histamine-induced itch and flare as that demon-
strated by nedocromil sodium, both when introduced
into the skin by iontophoresis and after applying it in a
new cutaneous emulsion (Altoderm™), designed to
optimise the penetration of SCG into the skin. We
further hypothesised that the response would be dose
related and the effect would be greater in atopic
subjects.
Methods
Thirty-five healthy volunteers (15 non-atopic and 20
atopic), with no sign of any skin disease participated in
this study, which was approved by the Southampton and
South West Hampshire Research Ethics Committee and
was conducted according to the Declaration of Helsinki.
All gave written informed consent to participate in the
studies.
At the first visit, the suitability of the subjects to take
part in the study was assessed and whether they met the
inclusion and exclusion criteria. Exclusion criteria
included pregnancy, the presence of skin disease and
taking drugs that might interfere with the study, includ-
ing corticosteroids, antihistamines, antidepressants and
psychotropic drugs. Atopic status was determined by
the presence of a history of allergic disease, and a posi-
tive skin prick test to house dust mite, grass pollen or
cat allergen. For the skin prick tests histamine and ster-
i l es a l i n ew e r eu s e da sp o s i t i v ea n dn e g a t i v ec o n t r o l s .
A positive response was defined as a wheal of more
than 3 mm greater than the negative control.
Iontophoresis
SCG (a gift from Hewlett Healthcare Ltd, Derby, UK.)
was introduced into the skin using iontophoresis
(MIC1-e, Moor Instruments Ltd, Axminster, Devon,
UK). The chamber was fixed to the skin, filled with a
4% solution of SCG in reverse osmosis purified water
and a total charge of 8 mC applied over a period of
40 seconds. It was calculated that this charge would
introduce 38.8 μg of SCG into the skin over an area of
approximately 0.8 cm
2 (1 cm diameter). At control sites,
the iontophoresis chamber was filled with reverse osmo-
sis purified water. Readings of blood flux were taken
before and 5 minutes after iontophoresis to assess any
drug- or iontophoresis-induced dermal vasodilatation.
SCG cutaneous emulsion
Subjects were supplied with 150 ml bottles containing
either the cutaneous emulsion base alone (vehicle) or
the emulsion with SCG at 1%, 2% or 4% w/w concentra-
tion (supplied by Hewlett Healthcare Ltd). The emul-
sions were identical in appearance and perception after
application to the skin.
Histamine challenge
Histamine (Sigma, Poole, Dorset, UK) dissolved in ster-
ile saline (0.9% NaCl) was injected intradermally (20 μl
of 1 μM or 300 nM) into the centre of the iontophoresis
sites or sites to which cutaneous emulsion had been
applied, 10 minutes after iontophoresis or 10 minutes
after the last application of the cutaneous emulsion. As
batches of histamine vary in their biological potency,
two concentrations of histamine were used so that the
most appropriate could be selected.
Scanning Laser Doppler Imaging
Wheal and flare areas and blood flux, indicative of der-
mal perfusion up to a depth of 1 mm, were assessed in
the skin using scanning laser Doppler imaging (Moor
LDI, Moor Instruments Ltd, Axminster, Devon, UK).
Ten minutes after histamine injection, an area of skin of
5 cm square was scanned giving ~16,000 data points for
analysis. Changes in weal and flare areas may be mea-
sured to an accuracy of ± 0.05 cm
2 and changes in per-
fusion to ± 5%.
Planimetry
While scanning laser Doppler imaging is ideal for asses-
s i n ga r e a so ff l a r ea n db l o o df l o w ,i ti sl e s sa c c u r a t ei n
determining the area of a wheal. Consequently, planimetry,
in which wheal areas were calculated from traces of their
outlines on acetate sheet, was used to confirm wheal size.
Severity of itch
Immediately following histamine injection, subjects
recorded the severity of itch on a 100 mm Visual Analo-
gue Scale (VAS) every 20 seconds for 5 minutes.
Preliminary investigation
On the first experimental day, subjects were asked to lie
down for 10 minutes prior to the commencement of the
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clean with antiseptic wipes (Sterets) and left to dry.
Four sites, two on the volar aspect of each forearm, one
for 1 μM histamine and the other for 300 nM histamine,
were selected for the study. The VAS score for itch for
1 μM histamine, 33.97 ± 5.35 mm, was greater than that
for 300 nM, 28.07 ± 4.25 mm. As a consequence, only
the results from the 1 μM histamine sites were used for
further calculations.
Three studies were conducted
Study 1: Iontophoresis study
Baseline blood flux was measured by scanning laser
Doppler imaging immediately before introduction of 4%
sodium cromoglicate in aqueous solution or reversed
osmosis purified water (ROW, control), were introduced
into the skin using iontophoresis. The order and sites of
iontophoresis of sodium cromoglicate and water were
randomised with the restriction that the treatments
were equally distributed between sites on the upper and
lower forearm. Five minutes after iontophoresis, blood
flux was reassessed using scanning laser Doppler ima-
ging. Ten minutes after iontophoresis, 20 μlo f1μMo f
histamine was injected intradermally and the subjects
began to record the severity of itch on a VAS. Ten min-
utes after histamine injection, the area of the weal was
measured using planimetry and the area and intensity of
the flare measured using scanning laser Doppler
imaging.
The techniques used for this study were similar to
those described in the original study with nedocromil
sodium [13].
Study 2: Effect of 4% SCG cutaneous emulsion
Subjects were given 2 bottles of emulsion labelled L1
and R1. Emulsion L1 was used on the left forearm and
emulsion R1 on the right. The containers contained
either 4% sodium cromoglicate emulsion or the match-
ing vehicle. Subjects were instructed to massage 1 ml of
the emulsion into two areas of each forearm, each
approximately 10 cm sq, delineated with a marker pen,
four times a day for 3 days prior to the next experimen-
tal visit. On the experimental day, the last application of
the emulsion was made 10 minutes before the injection
of 20 μlo f1μM of histamine. Recordings of itch, wheal
and flare made as in study 1. All interventions were
administered double-blind and randomised.
Study 3: Comparison of 1%, 2% and 4% SCG cutaneous
emulsions
Subjects were supplied with four bottles of emulsions
labelled A, B C and D. Subjects were instructed to mas-
sage 1 ml of emulsion A into an area of approximately
of 10 cm
2, delineated with a marker pen, on the upper
part of the volar surface of the left forearm four times a
day for 3 days prior to the next experimental day. In a
similar manner, emulsion B should be applied to the
lower part of the left forearm, emulsion C to the upper
part of the right forearm and emulsion D to the lower
part of the right forearm. On the experimental day, the
procedures followed were the same as in Study 2 with
the last application of the emulsions being made 10 min-
utes before the injection of 20 μlo f1μM of histamine.
T h ec o n t a i n e r sc o n t a i n e d1 % ,2 %o r4 %S C Ge m u l s i o n
or the matching vehicle. Treatments were randomised
and administered double-blind.
Statistical methods
All data are shown descriptively as means ± SEM for
each treatment. For VAS scores for itch, for each subject
the mean of all available values over the 5-minute per-
iod was used. A two-sided P-value of 0.05 was taken to
indicate statistical significance in any statistical testing.
For study 1, a generalised linear model was fitted to
the data incorporating atopic status, subject (within ato-
pic status), treatment and treatment x atopic status
interaction. If the interaction was not statistically signifi-
cant then this was dropped from the model. The least
square means for sodium cromoglicate and water are
presented together with the difference and 95% confi-
dence interval for the difference.
For study 2, the same method and model was used
and the contrast SCG 4% emulsion and vehicle
presented.
For study 3, a generalised linear model was fitted to
the data incorporating subject and treatment. If the
overall treatment effect was statistically significant then
pair-wise comparisons of each dose versus vehicle were
carried out. In addition, since the treatment groups con-
sisted of increasing concentrations of SCG, concentra-
tion (0, 1, 2, 4) was included in the model as a covariate
(with the subject factor only) in order to provide a test
of linear trend.
Since both studies 2 and 3 contained within subject
assessments of 4% concentration of SCG emulsion and
vehicle, a combined analysis using only atopic subjects
was carried out. A generalised linear model was fitted to
the data incorporating study, subject (within study),
treatment and treatment x study interaction. If the
interaction was not statistically significant then this was
dropped from the model. The least square means for
SCG emulsion and vehicle are presented together with
t h ed i f f e r e n c ea n d9 5 %c o n f i d e n c ei n t e r v a lf o rt h e
difference.
Checks that the underlying data were normally distrib-
uted were undertaken. The formal Shapiro-Wilk’st e s t
was satisfactory in all 8 analyses of both itch and flare.
Similarly, the distribution of residuals and normal
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fident that the parametric models used for the analyses
are appropriate.
Results
Study 1
Sixteen subjects, 8 atopic and 8 non-atopic, were included
in study 1. The results for itch and flare are summarised
descriptively and analysed statistically in Table 1.
The interaction between treatment and atopic status
was not statistically significant and was dropped from
the model for both symptoms. Atopic status was not
statistically significant for either symptom.
However, for the treatment effect, the results show
statistically significant inhibitions by SCG of the itch
response and flare area.
Study 2
Twelve subjects, 5 atopic and 7 non-atopic, were
included in study 2. The results for itch and flare are
summarised descriptively and analysed statistically in
Table 2.
The interaction between treatment and atopic status
was not statistically significant and was dropped from
the model for both symptoms. Atopic status was not
statistically significant for either symptom.
For the treatment effect in this study in which the
treatments were applied as topical cutaneous emulsions,
the results again show inhibitions by sodium cromogli-
cate of itch and flare area. However, only the effect for
flare area is statistically significant
Study 3
Seven subjects, all atopic, were included in study 3. The
results for itch and flare are shown in Table 3.
In this study 1% SCG cutaneous emulsion did
not inhibit the itch response (-5% inhibition) while
the 2% and 4%cutaneous emulsions inhibited the
response by 10% and 33% respectively. Against the
flare response, neither 1% nor 2% SCG inhibited the
response (-10% and -39% inhibitions respectively)
while the 4%cutaneous emulsion inhibited the
response by 26%. There was a statistically significant
difference between treatments for flare area but not
for the itch response.
The test for trend with increasing concentration was
statistically significant for itch response (P = 0.046), but
not for flare area (P = 0.22), thus suggesting an increas-
ing inhibition of itch response with increasing concen-
tration of SCG (Figure 1).
Combined analysis: SCG 4% v vehicle
SCG 4% cutaneous emulsion and vehicle were investi-
gated in both studies 2 and 3. In order to provide a
more precise comparison of the effects of SCG 4% com-
pared to vehicle, the 5 atopic subjects from study 2
were analysed together the 7 subjects (all atopic) from
study 3. Hence a total of 12 atopic subjects were
included in this analysis. The results for itch and flare
are summarised descriptively and analysed statistically in
Table 4.
The interaction between treatment and study was not
statistically significant and was dropped from the model
for both symptoms.
The treatment effect was statistically significant for
itch response and flare area, with SCG 4% showing inhi-
bition compared to vehicle in the combined analysis of
the atopic subjects (Figure 2).
There was no effect on the size of the wheal or blood
flux in any of the studies. These results are not shown.
Discussion
The results in study 1 of these challenge experiments
demonstrate the inhibition of the itch and flare
responses by SCG but with no effect on the wheal or
blood flux are in line with the previous observations
with the related chromone, nedocromil sodium [14,15].
The numbers in each individual study were small and
it was necessary to combine the results from the atopic
subjects in study 2 and study 3 to show that this SCG
Table 1 Effect of 4% SCG and reversed osmosis water (ROW) administered by iontophoresis on the itch and flare
responses to intradermal histamine
Symptom
(Measure)
SCG Mean ±
SEM
ROW Mean ±
SEM
SCG Least square
mean
ROW Least square
mean
Least square mean difference
(95%CI)
P
value
Itch (VAS mm) 23.24 ± 4.24 33.96 ± 5.35 23.24 33.96 10.72 (3.87,17.57 0.0045
Flare (cm
2) 16.28 ± 3.53 21.68 ± 3.35 16.55 21.94 5.39 (1.29,2.50 0.0143
Table 2 Effect of 4% SCG emulsion and vehicle on the itch and flare responses to intradermal histamine
Symptom
(measure)
SCG 4% emulsion
Mean ± SEM
Vehicle emulsion
Mean ± SEM
SCG Least square
mean
Vehicle square
mean
Least square mean
difference (95%CI)
P
value
Itch (VAS mm) 17.39 ± 3.82 20.29 ± 5.09 18.56 21.46 2.90 (-1.68,7.48) 0.19
Flare (cm
2) 22.96 ± 3.14 36.36 ± 3.94 23.12 36.52 13.40 (6.35,20.45) 0.0017
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subjects. This also shows in this formulation the drug is
able to penetrate intact skin in sufficient quantities to
have clinically demonstrable effects.
In study 3, sodium cromoglicate at 1%, 2% and 4%
concentrations gave inconsistent effects against the flare
responses. However, there was statistical evidence to
support an increasing effect on itch with increasing
concentration of sodium cromoglicate. The greatest
inhibition for both symptoms was seen with 4% concen-
tration. The cutaneous emulsion used in this study, is a
patented formulation for topical use containing 4% con-
centration of SCG in a novel emollient base designed to
improve the absorption through the skin of the water
soluble active ingredient SCG.
These results are supported by the results from a
recent study, in which subjects were challenged with
either intradermal allergen, intradermal codeine or intra-
dermal histamine after application of a placebo aqueous
cream, and creams containing 0.2%, 1%, and 4% SCG [9].
No intervention had any effect on wheal size or tempera-
ture change. The greatest effect on pruritus (itch) was in
the allergic group challenged with allergen in whom all
SCG treatments had a significant effect. In the non-aller-
gic subjects challenged with histamine, only the 4% con-
centration was significantly better than placebo.
SCG has no anti-histaminic activity [2]. Our unit has
shown that the drug is ineffective in preventing the
release of histamine from dispersed skin mast cells
derived from the foreskin of children [8]. It is unlikely
that in this study SCG is acting as a mast-cell stabiliser.
In the study in which the chromone NS was compared
with frusemide and bumetanide [15], all significantly
inhibited the itch and flare responses. The neurogenic
responses, itch and flare, could possibly result from sen-
sory nerve activation and axonal conduction, neuropep-
tide release, activation of neuropeptide receptors on
blood vessels and the ability of the vasculature to
respond to stimulation. As none of the drugs had any
effect on blood flux, it is unlikely that the mechanism of
Table 3 Comparison of 1%, 2% and 4% SCG emulsions and vehicle on the itch and flare responses to intradermal
histamine
Symptom (n) Vehicle emulsion Mean ± SEM SCG 1% Mean ± SEM SCG 2% Mean ± SEM SCG 4% Mean ± SEM P value
Itch (7) 20.89 ± 8.09 22.01 ± 8.46 18.7 ± 8.28 14.06 ± 4.08 P = 0.22
Flare (7) 19.37 ± 2.52 21.27 ± 3.05 26.87 ± 1.91 14.39 ± 1.45 P = 0.013












Figure 1 Effect of SCG emulsions and vehicle on A. itch and B.
flare. The effect of different concentrations of SCG cutaneous
emulsion and the vehicle emulsion on A. the severity of itch and B.
the area of flare induced by intradermal histamine. Yellow columns
= vehicle emulsion. Blue columns = SCG 1% concentration. Green
columns = SCG 2% concentration. Red columns = SCG 4%
concentration. Y axis: Severity of itch measured using 100 mm
Visual Analogue Scale. Flare area measured in cm
2. Statistical
Analysis for linear trend, p = 0.046 for itch, p = 0.22 for flare area.
Table 4 Effect of 4% SCG emulsion and vehicle on the itch and flare responses to intradermal histamine in atopic
subjects from studies 2 and 3
Symptom
(measure)
SCG 4% emulsion
Mean ± SEM
Vehicle emulsion
Mean ± SEM
SCG Least
square mean
Vehicle Least
square mean
Least square mean
difference (95%CI)
P
value
Itch (VAS mm) 17.88 ± 4.32 25.00 ± 6.34 18.67 25.79 7.13 (1.12,13.13) 0.024
Flare (cm
2) 19.11 ± 2.98 26.93 ± 4.02 20.33 28.16 7.82 (3.72,11.93) 0.0015
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Page 5 of 7action is on neuropeptide release, activation of neuro-
peptide receptors or a direct effect on the vasculature.
We reasoned and concluded that all three drugs inhib-
ited sensory nerve activation.
Conclusions
We conclude that the 4% SCG cutaneous emulsion used
in these studies will be useful in skin diseases such as
atopic dermatitis (eczema) and cutaneous mastocytosis
where itching is a predominant feature.
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